Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT05645718
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Dexamethasone Treatment for OSA in Children
- Conditions
- Interventions
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- The Hospital for Sick Children
- Target Recruit Count
- 10
- Registration Number
- NCT05638087
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
Dexamethasone, Olanzapine, Hemodynamics, and Ventilation in Cardiac Surgery
- Conditions
- Interventions
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 1200
- Registration Number
- NCT05635227
- Locations
- 🇩🇰
The Heart Centre, Rigshospitalet, Copenhagen, Denmark
Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone (DengDex Study)
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- Chulalongkorn University
- Target Recruit Count
- 200
- Registration Number
- NCT05631405
- Locations
- 🇹🇭
Chulalongkorn University, Bangkok, Thailand
🇹🇭King Chulalongkorn Memorial Hospital, Bangkok, Thailand
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, Lenalidomide or Elranatamab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Conditions
- Interventions
- First Posted Date
- 2022-11-21
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1116
- Registration Number
- NCT05623020
- Locations
- 🇮🇹
ASL PESCARA-Presidio Ospedaliero Pescara, Pescara, Italy
🇮🇹AOU Policlinico Umberto I, Roma, Italy
🇦🇺Pindara Private Hospital, Benowa, Queensland, Australia
Comparison of Caudal Blockade and Dorsal Penile Nerve Block With and Without the Intravenous Administration of Dexamethasone for Analgesia After Paediatric Male Circumcision
- Conditions
- Interventions
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Algemeen Ziekenhuis Maria Middelares
- Target Recruit Count
- 75
- Registration Number
- NCT05598255
- Locations
- 🇧🇪
AZ Maria Middelares Gent, Gent, Oost Vlaanderen, Belgium
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT05583617
- Locations
- 🇫🇷
IGR, Villejuif, France
🇦🇺Prince of Wales Hospital; Haematology, Randwick, New South Wales, Australia
🇦🇺St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Hellenic Society of Hematology
- Target Recruit Count
- 48
- Registration Number
- NCT05581875
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Hellenic Society of Hematology
- Target Recruit Count
- 36
- Registration Number
- NCT05573802
- Locations
- 🇬🇷
General Hospital of Athens "Alexandra", NKUA, Therapeutic Clinic, Athens, Greece
🇬🇷Anticancer Hospital of Thessaloniki "Theageneio", Thessaloniki, Greece
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 650
- Registration Number
- NCT05572515
- Locations
- 🇺🇸
Michael E DeBakey VA Medical Center, Houston, Texas, United States
🇨🇦Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇵🇹Uls Gaia Espinho, Vila Nova de Gaia, Portugal
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.